Journal Mobile Options
Table of Contents
Vol. 78, No. 4, 2006
Issue release date: November 2006
Pharmacology 2006;78:161–177

The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications

Wagner C. · Graninger W. · Presterl E. · Joukhadar C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Caspofungin, micafungin and anidulafungin are three drugs of the echinocandin class of antifungals available for intravenous treatment of invasive candidiasis and aspergillosis. They exhibit high in vitro and in vivo activities against Candida spp. and Aspergillus spp. In various clinical studies investigating candidemia and invasive candidiasis, Candida esophagitis, and fever in neutropenia, the clinical efficacy of the echinocandin tested was similar to that of established antifungals. Antifungal activity against strains no longer susceptible to conventional antifungal agents, such as fluconazole and amphotericin B suggests that echinocandins can be used as salvage therapy in life-threatening fungal infections. There is no cross-resistance to other antifungals. Excellent safety and tolerability of treatment with caspofungin has been documented over a total of 4.3 million patient days. Echinocandins are poor substrates of the cytochrome P450 enzyme family and can be safely co-administered with most drugs without the need for dosage adaptation. No dose reduction is required in renal impairment. A reduction in the daily maintenance dose has been recommended for caspofungin, but not for micafungin and anidulafungin in patients presenting with mild to moderate hepatic failure.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Beck-Sague C, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247–1251.
  2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–317.
  3. Moore CB, Sayers N, Mosquera J, Slaven J, Denning DW: Antifungal drug resistance in Aspergillus. J Infect 2000;41:203–220.
  4. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002;2:73–85.
  5. Denning DW: Echinocandins and pneumocandins – a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611–614.
  6. Petersen LA, Hughes DL, Hughes R, DiMichele L, Salmon P, Connors N: Effects of amino acid and trace element supplementation on pneumocandin production by Glarea lozoyensis: impact on titer, analogue levels, and the identification of new analogues of pneumocandin B(0). J Ind Microbiol Biotechnol 2001;26:216–221.
  7. Iwamoto T, Fujie A, Sakamoto K, Tsurumi Y, Shigematsu N, Yamashita M, Hashimoto S, Okuhara M, Kohsaka M: WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo) 1994;47:1084–1091.
  8. Nyfeler R, Keller-Schierlein W: Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components (in German). Helv Chim Acta 1974;57:2459–2477.
  9. Douglas CM: Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001;39(suppl 1):55–66.
  10. Kurtz MB, Rex JH: Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 2001;56:423–475.
  11. Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL: Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest 2005;128:3711–3716.
  12. Merck & Co: Cancidas Prescribing Information. Whitehouse Station, Merck, 2005.
  13. Fujisawa: Mycamine Prescribing Information. Deerfield, Fujisawa Healthcare, 2005.
  14. Pfizer: Eraxis Prescribing Information. New York, Pfizer, 2006.
  15. Debono M, Turner WW, LaGrandeur L, Burkhardt FJ, Nissen JS, Nichols KK, Rodriguez MJ, Zweifel MJ, Zeckner DJ, Gordee RS, et al: Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem 1995;38:3271–3281.
  16. Klis FM, de Groot P, Hellingwerf K: Molecular organization of the cell wall of Candida albicans. Med Mycol 2001;39(suppl 1):1–8.

    External Resources

  17. Bernard M, Latge JP: Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 2001;39(suppl 1):9–17.

    External Resources

  18. Douglas CM, Foor F, Marrinan JA, Morin N, Nielsen JB, Dahl AM, Mazur P, Baginsky W, Li W, el-Sherbeini M, et al: The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci USA 1994;91:12907–12911.
  19. Inoue SB, Takewaki N, Takasuka T, Mio T, Adachi M, Fujii Y, Miyamoto C, Arisawa M, Furuichi Y, Watanabe T: Characterization and gene cloning of 1,3-beta-D-glucan synthase from Saccharomyces cerevisiae. Eur J Biochem 1995;231:845–854.
  20. Mazur P, Morin N, Baginsky W, el-Sherbeini M, Clemas JA, Nielsen JB, Foor F: Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 1995;15:5671–5681.
  21. Beauvais A, Bruneau JM, Mol PC, Buitrago MJ, Legrand R, Latge JP: Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001;183:2273–2279.
  22. Mio T, Adachi-Shimizu M, Tachibana Y, Tabuchi H, Inoue SB, Yabe T, Yamada-Okabe T, Arisawa M, Watanabe T, Yamada-Okabe H: Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol 1997;179:4096–4105.
  23. Thompson JR, Douglas CM, Li W, Jue CK, Pramanik B, Yuan X, Rude TH, Toffaletti DL, Perfect JR, Kurtz M: A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol 1999;181:444–453.
  24. Douglas CM, D’Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB: Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997;41:2471–2479.
  25. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005;49:3264–3273.
  26. Osherov N, May GS, Albert ND, Kontoyiannis DP: Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002;46:2462–2469.
  27. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003;48:225–235.
  28. Miller CD, Lomaestro BW, Park S, Perlin DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006;26:877–880.
  29. Pelletier R, Alarie I, Lagace R, Walsh TJ: Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005;43:559–564.
  30. Hakki M, Staab JF, Marr KA: Emergence of a Candida krusei Isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006;50:2522–2524.
  31. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760–763.
  32. Clemons KV, Espiritu M, Parmar R, Stevens DA: Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006;50:1293–1297.
  33. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:739–746.
  34. Qadota H, Python CP, Inoue SB, Arisawa M, Anraku Y, Zheng Y, Watanabe T, Levin DE, Ohya Y: Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase. Science 1996;272:279–281.
  35. Kondoh O, Tachibana Y, Ohya Y, Arisawa M, Watanabe T: Cloning of the RHO1 gene from Candida albicans and its regulation of beta-1,3-glucan synthesis. J Bacteriol 1997;179:7734–7741.
  36. Popolo L, Gualtieri T, Ragni E: The yeast cell-wall salvage pathway. Med Mycol 2001;39(suppl 1):111–121.

    External Resources

  37. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999;33:75–80.
  38. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME: In vitro activity of micafungin (FK-463) against Candida spp: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002;46:3846–3853.
  39. Pfaller MA, Messer SA, Coffman S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother 1997;41:763–766.
  40. Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000;44:2310–2318.
  41. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002;46:1857–1869.
  42. Petraitiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999;43:2148–2155.
  43. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL: Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005;49:5058–5068.
  44. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46:3001–3012.
  45. Oakley KL, Moore CB, Denning DW: In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998;42:2726–2730.
  46. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM: Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001;45:3474–3481.
  47. Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F, Tawara S, Goto T, Matsumoto F, Kuwahara S: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000;44:619–621.
  48. Roberts J, Schock K, Marino S, Andriole VT: Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:3381–3388.
  49. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480–1489.
  50. Denning DW: Echinocandin antifungal drugs. Lancet 2003;362:1142–1151.
  51. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2339–2344.
  52. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739–745.
  53. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000;28:1274–1278.
  54. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC: Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004;48:815–823.
  55. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA: Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 2001;45:2018–2022.
  56. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I: Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005;45:1145–1152.
  57. Zeitlinger MA, Sauermann R, Traunmuller F, Georgopoulos A, Muller M, Joukhadar C: Impact of plasma protein binding on antimicrobial activity using time-killing curves. J Antimicrob Chemother 2004;54:876–880.
  58. Lyman CA, Walsh TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992;44:9–35.
  59. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D: Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49:1331–1336.
  60. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590–598.
  61. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005;57:759–764.
  62. Raasch RH: Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004;2:499–508.
  63. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA: Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536–4545.
  64. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ: Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317–3324.
  65. Benjamin DK, Jr., Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50:632–638.
  66. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005;33:676–682.
  67. Ugazio G, Artizzu M, Pani P, Dianzani MU: The changes in some hydrolytic enzymes in carbon tetrachloride-induced fatty livers. Biochem J 1964;90:109–116.
  68. Colburn DE, Giles FJ, Oladovich D, Smith JA: In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004;9:217–221.
  69. Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I: Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45:1018–1024.
  70. Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I: Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45:954–960.
  71. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48:4306–4314.
  72. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B: Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 2000;32:82–86.
  73. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, Bekersky I, Walsh TJ: Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001;45:3322–3327.
  74. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45:2845–2855.
  75. Nelson PW, Lozano-Chiu M, Rex JH: In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J Med Vet Mycol 1997;35:285–287.
  76. Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP: In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents 2006;27:174–177.
  77. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57–62.
  78. Manavathu EK, Alangaden GJ, Chandrasekar PH: In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus. J Antimicrob Chemother 1998;41:615–619.
  79. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW: Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998;42:873–878.
  80. Powles MA, Liberator P, Anderson J, Karkhanis Y, Dropinski JF, Bouffard FA, Balkovec JM, Fujioka H, Aikawa M, McFadden D, Schmatz D: Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:1985–1989.
  81. Ito M, Nozu R, Kuramochi T, Eguchi N, Suzuki S, Hioki K, Itoh T, Ikeda F: Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000;44:2259–2262.
  82. Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM, Queener SF, Smith JW: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996;40:1811–1816.
  83. Franzot SP, Casadevall A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997;41:331–336.
  84. Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, Motyl M: Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616–3623.
  85. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–2029.
  86. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623–3626.
  87. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149–3154.
  88. Arikan S, Yurdakul P, Hascelik G: Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother 2003;47:2640–2643.
  89. Graybill JR, Najvar LK, Luther MF, Fothergill AW: Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother 1997;41:1775–1777.
  90. Barchiesi F, Spreghini E, Baldassarri I, Marigliano A, Arzeni D, Giannini D, Scalise G: Sequential therapy with caspofungin and fluconazole for Candida albicans infection. Antimicrob Agents Chemother 2004;48:4056–4058.
  91. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA: Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003;51:1427–1429.
  92. Ninomiya M, Mikamo H, Tanaka K, Watanabe K, Tamaya T: Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice. J Antimicrob Chemother 2005;55:587–590.
  93. Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, Tawara S, Goto T, Watanabe Y, Matsumoto F, Kuwahara S: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000;44:614–618.
  94. Graybill JR, Bocanegra R, Luther M, Fothergill A, Rinaldi MJ: Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997;41:1937–1939.
  95. Ju JY, Polhamus C, Marr KA, Holland SM, Bennett JE: Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox–/– knockout mice. Antimicrob Agents Chemother 2002;46:1240–1245.
  96. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT: Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005;49:4895–4902.
  97. Warn PA, Sharp A, Morrissey G, Denning DW: In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002;50:1071–1074.
  98. van Vianen W, de Marie S, Ten Kate MT, Mathot RA, Bakker-Woudenberg IA: Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006;57:732–740.
  99. Sionov E, Mendlovic S, Segal E: Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2005.
  100. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564–2568.
  101. Luque JC, Clemons KV, Stevens DA: Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003;47:1452–1455.
  102. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH: Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox–/– mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006;50:422–427.
  103. Warn PA, Morrissey G, Morrissey J, Denning DW: Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003;51:913–919.
  104. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ: Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002;46:12–23.
  105. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004;190:1464–1471.
  106. Petraitis V, Petraitiene R, Groll AH, Bell A, Callender DP, Sein T, Schaufele RL, McMillian CL, Bacher J, Walsh TJ: Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;42:2898–2905.
  107. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–1402.
  108. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O’Brien S, Verstovsek S, Faderl S, Zhou X, Raad, II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH: Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143–147.
  109. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407–1416.
  110. Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA: Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004;53:878–881.
  111. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654–661.
  112. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T: Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021–2024.
  113. Dinubile MJ, Lupinacci RJ, Berman RS, Sable CA: Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses 2002;18:903–908.
  114. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529–1535.
  115. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451–457.
  116. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294–299.
  117. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002;31:183–187.
  118. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842–849.
  119. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770–775.
  120. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563–1571.
  121. Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA: Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005;50:196–205.
  122. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D: Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475–481.
  123. Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, Ngai AL, Kartsonis N, Chodakewitz J, Sable C: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004;6:110–116.
  124. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ: Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25–30.
  125. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111–180.
  126. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
  127. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE: Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005;45:227–233.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50